Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients

Table 1 Significant improvement of rash severity under specific dermatologic measures

Therapy	Patients (n)	ERSS (mean)		ERSS (mean)	Significance (P)
		Day 0	Day 21	Reduction
Mometason furoate cream (2x/d)	21	45.9	27.0	18.9	0.00009
Nadifloxacin 1% cream (1x/d) plus prednicarbate 0.25% cream (1x/d)	23	30.9	24.8	6.1	0.03
Nadifloxacin 1% cream (1x/d) plus prednicarbate 0.25% cream (1x/d) plus systemic isotretinoin (10-20 mg/d)	5	59.2	43.8	15.4	0.015

Patients with EGFRI-induced rash were treated with three different therapy regimens. All therapies resulted in a significant (P < 0.3) improvement of the severity of the skin rash (ERSS) after three weeks. Statistical analyses were performed applying the Student's t-test.

ISSN: 2047-783X